Annalise.ai vs Gleamer
Two European and Australian radiograph companies pointed at different films. Gleamer is musculoskeletal first, detecting fractures, effusions, dislocations and bone lesions, with a clearance covering both adult and paediatric use that is reported to be unique in that segment and a clearance study design stronger than most in this category. Annalise is chest first, with comprehensive findings coverage, regulatory footprints across several markets and greater deployment maturity. A department choosing between them is really choosing which queue to attack: the overnight trauma films or the chest backlog. Neither publishes a security attestation, which this index has recorded as a pattern across non United States imaging vendors rather than a fault unique to either, and Gleamer's multi party distribution makes the stewardship question harder to answer than it looks.
- The clearance is unusually specific, covering both adult and paediatric use for fracture detection, which is reported to be unique in that segment.
- The evidence base is one of the deepest in musculoskeletal imaging, and the clearance study design is a fully crossed multiple reader multiple case study rather than a retrospective sample.
- Distribution breadth substitutes for integration engineering, available directly and through several imaging platform partners.
- Comprehensive chest radiograph coverage across a large findings set with regulatory footprints in multiple markets, backed by a joint venture with a large radiology provider.
- Deployment maturity is greater, which matters for a modality where the failure is a subtle finding missed at scale rather than a dramatic error.
- For a health system standardising chest radiograph AI across sites, the more widely deployed platform carries fewer unknowns.
Side by Side
| Axis | A Annalise.ai |
G Gleamer |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These read different films for different purposes and should be compared per body region rather than on aggregate claims, since a trauma product and a chest product share almost no performance surface. Neither vendor publishes a security attestation or trust centre, which the index has recorded as a pattern across non United States imaging vendors rather than a fault unique to either. Gleamer's multi party distribution model makes the data stewardship question harder to answer, since no business associate terms were located and the responsible party varies by delivery path.